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In T lymphocytes, expression of miR-148a is induced by T-bet and Twist1, and is speciﬁc for pro-
inﬂammatory Th1 cells. In these cells, miR-148a inhibits the expression of the pro-apoptotic protein
Bim and promotes their survival. Here we use sequence-speciﬁc cholesterol-modiﬁed oligonucleotides
against miR-148a (antagomir-148a) for the selective elimination of pro-inﬂammatory Th1 cells in vivo. In
the murine model of transfer colitis, antagomir-148a treatment reduced the number of pro-inﬂammatory
Th1 cells in the colon of colitic mice by 50% and inhibited miR-148a expression by 71% in the remaining
Th1 cells. Expression of Bim protein in colonic Th1 cells was increased. Antagomir-148a-mediated
reduction of Th1 cells resulted in a signiﬁcant amelioration of colitis. The effect of antagomir-148a
was selective for chronic inﬂammation. Antigen-speciﬁc memory Th cells that were generated by an
acute immune reaction to nitrophenylacetyl-coupled chicken gamma globulin (NP-CGG) were not
affected by treatment with antagomir-148a, both during the effector and the memory phase. In addition,
antibody titers to NP-CGG were not altered. Thus, antagomir-148a might qualify as an effective drug to
selectively deplete pro-inﬂammatory Th1 cells of chronic inﬂammation without affecting the protective
immunological memory.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In the murine model of transfer colitis [1], chronic inﬂammationlation, Deutsches Rheuma-
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Ltd. This is an open access article uof the gut can be induced by effector memory T helper type 1 (Th1)
cells [2e4]. It is likely that Th lymphocytes are not only able to
induce, but also can maintain inﬂammatory bowel diseases, since
treatment of Crohn's disease patients with depleting anti-cluster of
differentiation 4 (CD4) antibodies did reduce disease activity
signiﬁcantly [5]. However, therapeutic ablation of CD4þ Th lym-
phocytes not only in Crohn's disease, but also in other chronic in-
ﬂammatory diseases, has been abandoned. Anti-CD4 induces long-
lasting lymphopenia and immunodeﬁciency, since also protective
Th lymphocytes are depleted [5e7]. Here we describe the in vivo
use of microRNA-148a (miR-148a)-speciﬁc antagomirs (antagomir-
148a) for the selective depletion of pro-inﬂammatory Th1 cells innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
P. Maschmeyer et al. / Journal of Autoimmunity 89 (2018) 41e5242the murine model of transfer colitis.
Recently, we have identiﬁed miR-148a as a microRNA (miRNA)
speciﬁcally upregulated in repeatedly activated Th1 cells, as
compared to Th2 and Th17 cells [8]. The T-box transcription factor
T-bet and the transcription factor twist-related protein 1 (Twist1),
two signature proteins of Th1 cells adapted to chronic inﬂamma-
tion, induce the upregulation of miR-148a. Both Twist1 and miR-
148a are highly expressed in effector/memory Th cells isolated
from inﬂamed tissues of patients with chronic inﬂammatory dis-
eases, including Crohn's disease and rheumatoid arthritis [8,9]. A
target of miR-148a is Bcl2l11, encoding the pro-apoptotic protein
Bcl2-interacting protein (Bim) [8,10e12]. Speciﬁc inhibition of miR-
148a in repeatedly activated murine Th1 lymphocytes in vitro, re-
sults in enhanced Bim expression and negatively affects their sur-
vival [8].
Antagomirs are 20e25 nucleotides long oligonucleotides com-
plementary to the mature form of distinct miRNAs and conjugated
to cholesterol at their 30 end. They easily penetrate into cells and
inhibit the activity of their target miRNAs, both in vitro and in vivo
[13,14]. Here we show that in the murine transfer colitis model,
systemic administration of antagomir-148a efﬁciently targets pro-
inﬂammatory Th1 cells in the inﬂamed gut, reducing their
numbers by 50%, and resulting in a mild but signiﬁcant ameliora-
tion of inﬂammation. This effect was selective for chronic inﬂam-
mation, since neither the maintenance nor the functionality of
protective CD4þmemory Th cells of the bone marrow (BM) and the
spleen were affected in healthy mice that were immunized with
NP-CGG to elicit vaccine-like immune responses. Thus, antagomirs
represent a novel class of therapeutic molecules that can be used to
target pro-inﬂammatory Th cells, which have adapted to chronic
inﬂammation by the selective expression of distinct miRNAs, here
miR-148a.
2. Material and methods
2.1. Mice
C57BL/6 mice were bred and housed under speciﬁc pathogen-
free (SPF) conditions at the animal facility of the DRFZ Berlin.
Recombination activating gene-deﬁcient (Rag1/) mice were bred
under SPF conditions at Charles River and housed in our animal
facility during experiments. All animal experiments were per-
formed in accordance with institutional, state, and federal guide-
lines. All experiments were approved by the federal state
institution “Landesamt für Gesundheit und Soziales” (G0300/11,
G0008/13, T0192/10) in Berlin, Germany.
2.2. Cell culture
Naive CD4þ Th cells were isolated from spleens of 6e12 weeks
old C57BL/6 mice. First, regulatory T cells were removed by staining
with cyanine 5 (Cy5)-coupled anti-CD25 antibodies and subse-
quent magnetic separation with anti-Cy5 microbeads (Miltenyi
Biotec). Afterwards, Th cells were stained with anti-CD4 ﬂuorescein
isothiocyanate (FITC) and puriﬁed by magnetic-activated cell sort-
ing (MACS®) using anti-FITC microbeads (Miltenyi Biotec). Finally,
naive CD4þCD62Lþ T cells were isolated by labeling of Th cells with
anti-CD62L microbeads (Miltenyi Biotec). To generate Th1 cells,
naive Th cells were stimulated with plate-bound anti-CD3 and anti-
CD28 antibodies (3 mg/ml each, BD Biosciences) in the presence of
CD90-depleted, irradiated (30 Gy) splenocytes, as well as anti-
interleukin 4 (IL-4) (10 mg/ml, clone 11B11) and the Th1-
polarizing cytokine IL-12 (5 ng/ml, R&D Systems). All T cell cul-
tures were conducted in “RPMI complete medium” (pH 7.2), i.e.
Roswell Park Memorial Institute-1640 (RPMI) medium (LifeTechnologies GmbH) containing 10% fetal calf serum (Th. Geyer),
100 units/ml penicillin, 0.1 mg/ml streptomycin and 10 mM b-
mercaptoethanol (all from Life Technologies GmbH). To avoid
activation-induced cell death, Th cells were removed from anti-
CD3/anti-CD28-coated plates before 48 h of stimulation and
transferred to new tissue culture plates. After 5 days of culture,
viable Th cells were puriﬁed by gradient separation with Ficoll
histopaque (Sigma-Aldrich), washed with PBS/BSA (i.e. phosphate-
buffered saline (PBS) including 0.2% bovine serum albumin (BSA),
pH 7.2) and re-stimulated for additional 5 days under the same
conditions, except that IL-2 (10 ng/ml, R&D Systems) was added to
the cultures. Polarization of Th cells to Th1 lymphocytes was
determined by measuring interferon-g (IFN-g) expression by ﬂow
cytometry following phorbol 12-myristate 13-acetate (PMA)/ion-
omycin stimulation.2.3. Antagomirs
Lyophilized antagomirs were custom-synthesized according to
Krutzfeldt et al. (2005) [13]. Antagomirs were generated by Dhar-
macon, GE Healthcare, for in vivo applications. Puriﬁcation of both
antagomir-148a and antagomir-Scrambled (antagomir-Scr) was
performed by high performance liquid chromatography (HPLC) and
contained similarly low concentrations of endotoxins, with 0.218
EU/mg (endotoxin units per milligram) for antagomir-148
and  0.2 EU/mg for antagomir-Scr. Antagomir sequences are as
follows: antagomir-Scr 5-mU(*)mC(*)mAmCmGmCmAmGmAmU-
mUmCmAmUmA-mA(*)mC(*)mG(*)mU(*)-3-Chol [15]; and
antagomir-148a 5-mA(*)mC(*)mAmAmAmGmUmUmCmUmGmU-
mAmGmUmGmCmAmC(*)mU(*)mG(*)mA(*)-3-Chol [8]. All ribo-
nucleotides were 2-O-methyl modiﬁed (mN) and (*) represents a
phosphorothioate modiﬁcation of the backbone. At the 30-end of
the oligonucleotides, a cholesterol (Chol) molecule was added.
Lyophilized antagomirs were dissolved in PBS (pH 7.2) at the
desired concentration at room temperature for 30 min with slight
shaking [14].2.3.1. Colitis induction and antagomir treatment
Two weeks prior to colitis induction, Rag1/ recipient mice
were colonized by oral gavage with fecal bacteria suspensions
containing segmented ﬁlamentous bacteria (SFB) and Helicobacter
species (H. spp.) [16]. In order to conﬁrm whether the Rag1/ mice
were colonized successfully, PCRs of fecal DNA with the following
primers were conducted: H. spp. Fw: 50-ctatgacgggtatccggc-30, Rv:
50-attccacctacctctccca-30, SFB Fw: 50-gacgctgaggcatgagagcat-30, Rv:
50-gacggcacggattgttattca-3. In order to ensure comparable com-
positions of the intestinal microbiota in antagomir-148a- and in
antagomir-Scr-treated (i.e. control) groups throughout the experi-
ments, mice of both groups were co-housed in identical cages
during the experiment.
Colitis was induced as published before with small modiﬁca-
tions [1]. In brief, repeatedly activated Th1 cells were resuspended
in PBS (pH 7.2) in order to transfer 4  105 cells into Rag1/ re-
cipients via intravenous (i.v.) injections into the lateral tail vein. On
days 2, 4 and 6 after Th1 cell transfer, mice were injected i.v. with
50 mg/kg antagomir-Scr or with antagomir-148a. During ongoing
experiments, health conditions of mice were monitored according
to the guidelines of the “Landesamt für Gesundheit und Soziales” in
Berlin and experiments were terminated according to the same
guidelines. The severity of inﬂammation was evaluated by
measuring the length and the weight of the colon to calculate its
weight-to-length ratio, which for healthy colons of mice of that age
typically is in the range of 35e40 and which increases with higher
degrees of inﬂammation [17e19].
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responses
C57BL/6 mice were intraperitoneally (i.p.) immunized with
100 mg NP-CGG and 100 ml incomplete Freund's adjuvant (IFA).
Three weeks later, mice were boosted i.p. with 10 mg NP-CGG and
100 ml IFA. One, 3 and 5 days after boost, micewere injected i.v. with
50 mg/kg antagomir-148a or antagomir-Scr. On day 7 after boost,
mice were sacriﬁced to analyze immune cell populations by ﬂow
cytometry. Non-immunized control mice were age-matched lit-
termates of immunized mice but were not immunized with NP-
CGG and were not treated with antagomirs.
In order to determine T memory cells in the memory phase after
immunization and also to generate NP-CGG-speciﬁc antibody titers
by long-lived plasma cells, C57BL/6 mice were immunized as
described above, but were boosted twice i.p. with 10 mg NP-CGG
and 100 ml IFA with a 3 week interval in between. Mice were left
untreated for additional 3 weeks before they were treated 3 times
every second day i.v. with 50 mg/kg antagomir-148a or antagomir-
Scr. Two days after the third treatment, sera of mice were collected
to determine antibody titers by Enzyme-linked Immunosorbent
Assay (ELISA). Subsequently, the mice were sacriﬁced, in order to
analyze immune cell populations from the spleen and the bone
marrow by ﬂow cytometry. Non-immunized control mice were
age-matched littermates of immunized mice but were not immu-
nized with NP-CGG and were not treated with antagomirs.
2.3.3. Isolation of leukocytes from the colonic mucosa
Puriﬁcation of leukocytes from the colon was performed as
described before [20]. Fat tissues were removed from intestines
before the colons were opened longitudinally and washed with PBS
(pH 7.2). The epithelial layers were removed by 2 cycles of incu-
bation in Ca2þ/Mg2þ-free Hank's Balanced Salt Solution (HBSS, pH
7.2) with 5 mM ethylenediaminetetraacetic acid (EDTA) and 10mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, pH
7.2) for 20 min at 37 C while gently spinning at 100 rotations per
minute (rpm). Afterwards, the intestines were cut into small pieces
and digested 3 times 20 min each at 37 C with HBSS (pH 7.2)
containing Ca2þ/Mg2þ and 0.5 mg/ml Collagenase D (Roche),
0.5 mg/ml DNase I (Sigma-Aldrich) and 0.5 U/ml Dispase (BD Bio-
sciences) while agitated gently at 300 rpm. After digestion, cells
were ﬁltered (100 mm cell strainers, BD) into single cell suspensions
and washed with PBS/BSA (pH 7.2) prior to antibody staining for
ﬂow cytometry or cell sorting.
2.4. Flow cytometry
Erythrocytes of single cell suspensions from spleen and BM
were lysed. T cell cultures or single cell suspensions of leukocytes
isolated from BM, inguinal lymph nodes (iLNs), spleen or colon
were stained in PBS/BSA (pH 7.2) with EDTA (2 mM) after blocking
with anti-mouse CD16/CD32 (2.4G2) antibodies. Surface antibody
stainings were performed for 15 min at 4 C.
For intracellular cytokine stainings, cells were re-stimulated for
4 h with 10 ng/ml PMA and 1 mg/ml ionomycin in RPMI complete
medium at 37 C, 5% CO2. After 1 h of incubation, Brefeldin A
(Biolegend) was added to the cultures to reach a ﬁnal concentration
of 5 mg/ml. Cells were washed and stained with ﬁxable viability dye
in PBS (pH 7.2) for 15 min at 4 C using the Zombie Yellow™ Fixable
Viability Kit from Biolegend. Subsequently, the cells were ﬁxed and
stained intracellularly using the Fixation/Permeabilization Solution
Kit from BD Biosciences. To avoid unspeciﬁc stainings, cells were
blocked again with anti-mouse CD16/CD32 (2.4G2) after ﬁxation
and permeabilization of the cells. For detection of NP-CGG-speciﬁc
T lymphocytes from BM, cells and splenocytes isolated from onemouse were stimulated together in one well (1:1 ratio) for 6 h at
37 C, 5% CO2. In order to distinguish splenocytes from BM cells,
splenocytes were labeled with CFSE (1 mM,10 min at 37 C, 5% CO2)
prior to stimulation with NP-CGG. After the ﬁrst 2 h of stimulation,
Brefeldin A (5 mg/ml ﬁnal concentration) was added to the cultures.
Subsequently, cells were stained intracellularly for cytokines and
CD40L as described for cells stimulated with PMA/ionomycin
above.
Transcription factor stainings were performed using the
forkhead-box-protein P3 (FoxP3) staining buffer kit (eBioscience)
according to the manufacturer's instructions. For intracellular Bim
and B-cell lymphoma 2 (Bcl-2) stainings, cells were ﬁxed over-night
using the FoxP3 staining buffer set, then washed and blocked with
130 mg/ml rat immunoglobulin G2a (IgG2a) and 130 mg/ml arme-
nian hamster IgG in addition to anti-mouse CD16/CD32 for 30 min
in the fridge. Afterwards, cells were stained for Bim and Bcl-2 at
4 C over-night. Cells were recorded on a Fluorescence-activated
Cell Sorting (FACS) Canto II instrument (BD Biosciences) or on a
MACSQuant (Miltenyi Biotec). The following antibodies and re-
agents were used: Bcl-2 phycoerythrin (PE) (3F11, BD Biosciences),
Bim Alexa Fluor 647 (14A8, Merck Millipore, Darmstadt, Germany),
CD3 allophycocyanin (APC)-eFluor 780 (145-2C11, eBioscience),
CD1d-PBS57-loaded tetramer PE (NIH tetramer core facility), CD4
PE-Cy7 (RM4-5, eBioscience), CD8 Cy5 (53e6.72, own conjugate),
CD40L Alexa Fluor 647 (MR1, eBioscience), CD40L PE (MR1, Bio-
legend), CD44 Paciﬁc Blue (IM7, own conjugate), CD64 APC (X54-5/
7.1, eBioscience), CD69 FITC (H1.2F3, own conjugate), CD138 bril-
liant violet 421 (BV421) (281-2, Biolegend) FoxP3 eFluor 450 (FJK-
16 s, eBioscience), GATA-binding protein-3 (GATA-3) peridin chlo-
rophyll protein complex (PerCP)-eFluor710 (TWAJ, eBioscience), IL-
2 PE and APC (JES6-5H4, Biolegend), IL-10 PE (JES5-16E3, eBio-
science), IL-17A FITC (TC11-18H10.1, Biolegend), IL-22 APC (IL22JOP,
eBioscience), Ki-67 Alexa Fluor 488 (B56, eBioscience), Ly-6C Paciﬁc
Blue (HK1.4, Biolegend), Ly-6G PerCP-Cy5.5 (1A8, Biolegend), pro-
pidium iodide (PI, Sigma Aldrich), ROR-gt PE (Q31-378, BD Bio-
sciences), T-bet Alexa Fluor 647 (4B10, Biolegend), tumor necrosis
factor-a (TNF-a) Alexa Fluor 405 (MP6-XT22, own conjugate). The
gating of the ﬂow cytometric data was performed according to the
guidelines for the use of ﬂow cytometry and cell sorting in
immunological studies [21].
2.5. Cell sorting and quantitative PCR
CD3þCD4þ Th cells from the colonic lamina propria were sorted
using a FACSAria I sorter (BD Biosciences). Cells were lysed and total
RNA was puriﬁed with the Quick-RNA™ MiniPrep kit (Zymo
Research). Mature miR-148a and U6 small nuclear RNA (snRNA)
were detected by quantitative PCR with the Taqman MicroRNA
Reverse Transcription kit in combination with TaqMan MicroRNA
Assays (Applied Biosystems) according to the manufacturer's rec-
ommendations. For normalization, the expression values were
compared to values of snU6 RNA by the change-in-threshold
method (2DCT).
2.6. Enzyme-linked Immunosorbent Assays
Maxisorp ELISA 96-well plates were coated with 2 mg/ml NP-
CGG in PBS (pH 7.2) (over-night at 4 C). Afterwards, the plates were
blocked for 1 h at room temperature with PBS (pH 7.2) including 2%
BSA and 0.05% Tween and rinsed twice with tap water. The sera
were initially diluted by a factor of 200, followed by 3 serial 1:100
dilutions in PBS (pH 7.2) with 2% BSAþ 0.05% Tween. The sera then
were transferred to the NP-CGG-coated plate and incubated for
2e3 h at room temperature. Subsequently, the plates were washed
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labeled antibodies (1 mg/ml) for 1 h at room temperature. The
plates were washed again and 50 ml developing solution (one tablet
of nitrophenyl phosphate in 5 ml 1 M diethanolamine, pH 9.8
(Sigma-Aldrich)) was added to each well. After 10, 15, 30 and
45 min, the absorbance at 405 nm was determined by a plate
reader.
2.7. Histology
Organs were dissected from mice and ﬁxed in 4% para-
formaldehyde at 4 C over-night. Subsequently, the organs were
washed with PBS (pH 7.2), dewatered and embedded in parafﬁn.
Tissue sections were prepared and stained with hematoxylin and
eosin.
2.8. Statistics
If not stated otherwise, the ManneWhitney test for unpaired
data was used for all statistical analyses with *, ** and *** repre-
senting p values of <0.05, <0.01 or <0.001, respectively. The pro-
gram GraphPad Prism was used for all statistical analyses.
3. Results
3.1. Antagomir-148a depletes pro-inﬂammatory Th1 cells in
inﬂamed colons of mice with colitis
Th1 cells adapt to repeated stimulation by upregulating the
expression of miR-148a in vitro, which promotes their survival [8].
To investigate whether such pro-inﬂammatory Th1 cells can be
targeted by inhibiting miR-148a function in vivo, we used the Th
cell-dependent transfer colitis model [1]. In this model, the in-
duction of colitis requires transfer of Th cells into immunodeﬁcient
mice (e.g., Rag1-deﬁcient mice). Accordingly, we induced inﬂam-
mation of the colon by adoptive transfer of repeatedly activated Th1
cells into Rag1-deﬁcient mice (Fig. 1A). Within 11 days after
transfer, the recipient mice developed colitis as shown by weight
loss and diarrhea. On days 2, 4 and 6 after adoptive transfer, 50 mg/
kg miR-148a-speciﬁc antagomirs (antagomir-148a) or antagomirs
with a non-targeting control sequence (antagomir-Scr) were
injected i.v. into these mice (Fig. 1A). The experiment was termi-
nated before the ﬁrst mouse had lost 20% of its initial body weight
and cells from inﬂamed colons and spleens were analyzed. More
than 90% of Th cells in the inﬂamed colons were T-bet-expressing
Th1 cells, with less than 5% of Th cells expressing ROR-gt, GATA-3 or
FoxP3 (Supplemental Fig. 1A). Approximately 70% of all Th cells
expressed IFN-g, of which ~20% also expressed TNF-a
(Supplemental Fig. 1B). In contrast, fewer than 5% of Th cells
expressed IL-17A, IL-22 or IL-10 (Supplemental Fig. 1B). Compared
to mice treated with antagomir-Scr, antagomir-148a-treated mice
showed a 50% depletion of CD4þ Th cells in the colon (Fig.1B and C).
In the spleen, Th cell numbers were not signiﬁcantly different
(Fig. 1C). In the colons of antagomir-148a-treated mice, the number
of IFN-gþ Th1 cells was reduced by 47% (Fig. 1D). In contrast, IL-10-
(Fig. 1E), IL-17A- (Fig. 1F) or IL-22- (Fig. 1G) producing Th cells wereFig. 1. Systemic antagomir-148a treatment of colitic mice depletes IFN-g-expressing
experimental procedure for inducing colitis by adoptive transfer of repeatedly activated Th
plots showing the frequencies of CD3þCD4þ Th cells isolated from inﬂamed colons of colitic m
percentages of Th cells among isolated viable cells. (C) Total cell numbers of viable CD3þC
antagomir-148a or antagomir-Scr treatment as shown in (A). (DeG) Lymphocytes from colit
the presence of Brefeldin A. Shown are the absolute cell numbers of CD3þCD4þ Th cells tha
myeloid subsets isolated from inﬂamed colonic mucosae of colitic mice. Depicted data are p
and antagomir-Scr-treated mice, respectively.not reduced. Antagomir-148a treatment also did not affect the
numbers of total CD3-negative myeloid cells, Ly6ChiCD64þ mono-
cytes or Ly6CloCD64þmacrophages in the colon, while the numbers
of Ly6Gþ neutrophilic and SiglecFþ eosinophilic granulocytes were
reduced by 25% and 37%, respectively (Fig. 1H).
3.2. Antagomir-148a reduces the expression of miR-148a while
enhancing the expression of Bim in colonic Th1 cells
From the inﬂamed colons of colitic mice, Th cells surviving the
antagomir-148a treatment were isolated on days 9 or 11 after T cell
transfer, and analyzed for expression of miR-148a, Bim and Bcl-2.
The expression of miR-148a, as determined by quantitative PCR,
was reduced by 71%, when compared to Th cells isolated from the
colons of mice treated with antagomir-Scr (Fig. 2A). Expression of
the pro-apoptotic protein Bim, one of the targets of miR-148a, was
upregulated by 15%, as determined by cytometric immunoﬂuores-
cence of individual Th cells (Fig. 2B and C, left panels). In the same
cells, expression of the anti-apoptotic protein Bcl-2 was not
affected (Fig. 2B and C, right panels), showing that inhibition of
miR-148a skews the balance of pro- and anti-apoptotic molecules
in Th cells in favor of pro-apoptotic proteins, as has been shown
before in vitro [8]. The unimodal staining for Bim in CD4þ T cells
from the colon shows that all T cells were affected by the antagomir
treatment, and not just a subpopulation (Fig. 2B).
3.3. Antagomir-148a ameliorates colitis
To quantify colitis pathology, we analyzed disease parameters
such as body weight loss, the weight-to-length ratios of inﬂamed
colons and the histology of the inﬂamed colons from mice treated
as shown in Fig. 1A. Both mice treated with antagomir-148a and
mice treated with antagomir-Scr showed signs of colonic inﬂam-
mation, such as inﬁltration of immune cells, goblet cell loss, hy-
perplasia and crypt abscesses (Supplemental Fig. 2). However, and
in conjunction with the ablation of Th1 cells, mice treated with
antagomir-148a showed a signiﬁcant weight loss delay during the
inﬂammatory late phase of colitis, when compared to mice treated
with antagomir-Scr (Fig. 3A). Antagomir-148a-treatedmice showed
a signiﬁcant amelioration of colon inﬂammation as reﬂected by a
20% reduction of the colonic weight-to-length ratio (Fig. 3B). Of
note, systemic ablation of CD4þ T lymphocytes by injection of anti-
CD4 antibodies (clone GK1.5) causing a depletion of 99% of CD4þ T
cells both in spleen and colon (Supplemental Figs. 3A and B),
resulted in a similar amelioration of inﬂammation as determined by
weight loss delay during the inﬂammatory late phase of colitis and
histology (Supplemental Figs. 3C and D).
3.4. Antagomir-148a does not affect the immunological memory
during the effector phase of an acute immune response
To investigate whether the reduction of Th cells by systemic
inhibition of miR-148a is speciﬁc for pro-inﬂammatory Th1 cells
and does not interfere with protective memory Th cells generated
by vaccine-like immune responses, we immunized healthy C57BL/6
mice i.p. with 100 mg NP-CGG and IFA (Fig. 4A). After 21 days, weTh1 cells selectively in the inﬂamed colon. (A) Schematic overview depicting the
1 cells into Rag1/ mice and subsequent antagomir treatment. (B) Representative dot
ice that were treated with antagomir-Scr or antagomir-148a. Displayed frequencies are
D4þ Th cells that were isolated from the colons and spleens of colitic mice following
ic mice were isolated from the inﬂamed colons and stimulated with PMA/ionomycin in
t expressed IFN-g (D), IL-10 (E), IL-17A (F) or IL-22 (G). (H) Quantiﬁcation of different
ooled from two independent experiments with n ¼ 12 and n ¼ 13 for antagomir-148a-
Fig. 2. Systemic antagomir-148a treatment efﬁciently inhibits miR-148a expression and results in upregulation of Bim protein in Th cells of the inﬂamed intestinal mucosa
in colitic mice. Colitic Rag1-deﬁcient mice were treated with antagomir-148a or antagomir-Scr as displayed in Fig. 1A. (A) On the last day of the experiment, CD3þCD4þ Th cells
were isolated from the colonic laminae propriae by FACS. RNA from the sorted cells was puriﬁed and miR-148a expression was measured by TaqMan™ PCR. (B, C) Colonic Th cells
were analyzed by ﬂow cytometry following intracellular staining of the pro-apoptotic molecule Bim (B, C left panels) and the anti-apoptotic molecule Bcl-2 (B, C right panels).
Shown are representative histograms (B) and the quantiﬁcation of geometric means normalized to antagomir-Scr-treated mice (C). Data in (A) are pooled from two independent
experiments with n ¼ 10 and n ¼ 8 mice, while data in (C) are pooled from two independent experiments with n ¼ 12 and n ¼ 13 mice that were treated with antagomir-148a or
antagomir-Scr, respectively.
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i.v. with either 50 mg/kg antagomir-148a or antagomir-Scr on days
1, 3 and 5 after the boost, i.e. during the effector phase of the im-
mune response. On day 7 after boost, we determined the cell
numbers of CD4þ and CD8þ memory T cell subsets in the spleen.
The numbers of all investigated memory T cell subsets were un-
changed upon antagomir-148a treatment and in antagomir-Scr-
treated controls (Fig. 4B and C). Importantly, antagomir-148a
treatment did also not reduce NP-CGG-speciﬁc CD40Lþ memory
Th cells as well as their functionality reﬂected by production of IFN-
g upon re-stimulation with NP-CGG (Supplemental Figs. 4A and B).
MiR-148a is also expressed in plasmablasts and plasma cells in
which its expression accounts for 20% of all expressed microRNAs
[12], hence antagomir-148a treatment could potentially affect
antibody-secreting cells. However, 6 days after initial antagomir-
148a treatment, NP-CGG-speciﬁc immunoglobulin G (IgG) anti-
body titers in the serum were not altered (Fig. 4D). Of note, anta-
gomir injections did not have any detrimental effects on the
structure and architecture of highly perfused organs such as the
liver, heart, kidney or lung (Supplemental Fig. 5). Finally,
antagomir-148a treatment did also not change the numbers of
FoxP3þ T regulatory cells in the spleen (Supplemental Fig. 6).3.5. Antagomir-148a does not affect the resting immunological
memory
To test whether antagomir-148a affects “protective”, resting
memory Th cells generated by vaccine-like immune responses, we
immunized C57Bl/6 mice with NP-CGG and IFA and injected them
with antagomir-148a in thememory phase following contraction of
the immune response as indicated in Fig. 5A. We measured the
absolute numbers of splenic NP-CGG-speciﬁc Th memory cells by
determining CD44þCD40Lþ Th memory cells upon re-stimulation
with NP-CGG ex vivo. Antagomir-148a treatment did not reduce
the frequencies (Fig. 5B) or absolute cell numbers (Fig. 5C) of
CD40Lþ Th memory cells. Regarding cytokine expression, NP-CGG-
speciﬁc memory Th cells were not affected in producing IFN-g
(Fig. 5D and E), TNF-a (Fig. 5D and F) or IL-2 (Fig. 5D and G) after
treatment with antagomir-148a. In accordance to the unaltered
pool of NP-CGG-speciﬁc memory Th cells, we also did not observe
differences in the serum titers of NP-CGG-speciﬁc IgG in mice that
were treated with antagomir-148a or antagomir-Scr (Fig. 5H).
We have previously shown that protective memory Th cells that
had been generated by vaccine-like induced immune responses
migrate to the bone marrow and express the markers CD69 and
Ly6C [22,23]. In order to test whether antagomir-148a treatment
Fig. 3. Antagomir-148a treatment moderately ameliorates pathology of colitis. Colitis was induced in Rag1/mice prior to their treatment with antagomirs as shown in Fig. 1A.
(A) The weight loss relative to starting weight was monitored during the experiment. (B) At the end of the experiment, mice were sacriﬁced and the weight-to-length (WeL) ratios
of the colons were determined. Displayed data are pooled from two independent experiments. The Two-Way ANOVA test was used to determine the overall statistical signiﬁcance of
total body-weight loss curves between antagomir-148a- and antagomir-Scr-treated mice. Bonferroni multiple comparison was used as a post-hoc test to evaluate the signiﬁcance of
single time points. Shown data are pooled from two independent experiments with n ¼ 12 and n ¼ 13 for antagomir-148a- and antagomir-Scr-treated mice, respectively. Depicted
curves in (A) represent the median weight per designated group.
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natural exposure to antigens, we determined the absolute numbers
of BM CD4þ memory T cells expressing CD69 and/or Ly6C, 6 days
after the ﬁrst antagomir treatment as depicted in Fig. 5A. No dif-
ferences were detectable betweenmice treated with antagomir-Scr
and antagomir-148a (Fig. 6A). This was also true for CD8þ T
memory cells in the bone marrow (Fig. 6B) and both for CD4þ and
CD8þ memory T cell populations in the spleen and in lymph nodes
(Supplemental Figs. 7AeD). Following PMA/ionomycin stimulation,
the frequencies of IFN-g- and TNF-a-expressing Th lymphocytes
among memory Th cells were not signiﬁcantly different in BM,
spleen and lymph nodes of mice treated with antagomir-148a or
with antagomir-Scr (Supplemental Fig. 7 EeJ). Of note, also resting
NP-CGG-speciﬁc BM memory Th cells that were generated by
controlled immunization as shown in Fig. 5A were unaltered after
antagomir-148a treatment (Fig. 6C and D). Together, these data
show that antagomir-148a does not ablate resting memory Th cells
that had been generated in “protective” immune responses with a
ﬁnite presence of antigen, as opposed to Th1 cells of a chronic
immune reaction.4. Discussion
The role of pro-inﬂammatory Th1 lymphocytes in chronic in-
ﬂammatory diseases is still controversially discussed [24e26].
Generic depletion of bulk Th lymphocytes by anti-CD4 treatment
has been reported to ameliorate chronic inﬂammatory bowel dis-
ease [5]. However, this treatment strategy has been abandoned due
to two signiﬁcant drawbacks. First, this treatment has been shown
to induce a long-lasting lymphopenia in patients [5]. Second, Th cell
depletion by anti-CD4 antibodies does not distinguish between
pathogenic and protective memory Th cell subsets [5]. To date, no
therapeutic option for the selective ablation of pathogenic Th1
lymphocytes driving chronic inﬂammation is available.
In the murine model of transfer colitis, intestinal inﬂammation
can be induced and maintained by Th1 cells [2e4]. Th lymphocytes
isolated from the inﬂamed guts of patients suffering from Crohn's
disease are enriched for Th1 cells expressing high levels of themaster transcription factor T-bet, activated signal transducer and
activator of transcription-4 (STAT4) and, upon re-stimulation, the
effector cytokine IFN-g [27], suggesting a direct involvement of Th1
cells in the pathogenesis of the disease [24]. They also express high
levels of TWIST1, unlike Th lymphocytes isolated from healthy colon
and blood [9]. Expression of Twist1 - an E-box binding transcription
factor - increments after repeated activation of Th1 lymphocytes
[9]. Together with T-bet, Twist1 induces the expression of miR-
148a. In repeatedly activated Th1 cells, miR-148a represses Bim
and thus promotes their survival [8]. Here we demonstrate that
systemic treatment of colitic mice with antagomir-148a selectively
ablates Th1 cells from their inﬂamed colons. Memory T cells of
spleen and bone marrow, including Th1 memory cells, are not
depleted in healthy mice after immunization. Finally, humoral
immune responses were also not altered by this treatment.
MiR-148a is a member of the miR-148/-152 family, together
with miR-148b and miR-152 [14,28]. Expression of miR-148a has
been reported for kidney glomerular cells [29], dendritic cells [30],
thrombocytes [31], plasma cells [12], B cells [11], repeatedly acti-
vated Th1 lymphocytes [8], and a variety of cancer cells, e.g. in renal
cell carcinoma [32]. Multiple miR-148a targets have been identiﬁed
including the gene Bcl2l11 encoding for the pro-apoptotic protein
Bim [8,10e12]. Knocking down the physiological expression of miR-
148a results in enhanced expression of Bim in glioblastoma cells
[10], plasma cells [12] and repeatedly activated Th1 cells [8]. By
regulating expression of Bim, miR-148a favors the survival of cells
expressing it. In vitro, antagomir-mediated inhibition of miR-148a
impairs the viability of glioblastoma and repeatedly activated Th1
cells [8,10]. Here we show, that antagomir-148a treatment of colitic
mice resulted in an efﬁcient knock-down of miR-148a in pro-
inﬂammatory Th1 cells of the inﬂamed colon. Our results conﬁrm
a previous report that showed that antagomirs can be utilized as a
systemic treatment in that they are resistant to degradation by
RNases following injection into an organism [13]. Further, they
demonstrate that antagomir-148a penetrates into pro-
inﬂammatory Th1 lymphocytes residing in the inﬂamed colon. In
this manner, antagomir-148a treatment is suitable for manipu-
lating gene expression in vivo also in the inﬂamed tissue. Indeed,
Fig. 4. Antagomir-148a treatment during the effector response of an acute immune reaction does not reduce memory T cell populations or circulating antigen-speciﬁc IgG
titers. (A) Schematic diagram showing the experimental procedure for eliciting a vaccine-like induced immune response and subsequent antagomir treatment during the effector
phase after boosting with NP-CGG and IFA. (B, C) Cell numbers of splenic memory T cell populations in immunized mice that were treated with antagomir-148a or antagomir-Scr as
shown in Figure 4A. (D) Blood sera of mice that were treated as shown in (A) were collected on day 28 and NP-CGG-speciﬁc antibody titers were determined by ELISA. Data in (B)
and (C) are pooled from two independent experiments with n ¼ 11 antagomir-Scr-treated mice and n ¼ 12 antagomir-148a-treated mice. Data in (D) are from one experiment with
n ¼ 7 for both antagomir-148a- and antagomir-Scr-treated mice.
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remaining Th1 cells of the colon following inhibition of miR-148a
by antagomir-148a injections. These results resemble what we
previously have observed for repeatedly activated Th1 cells in vitro
[8], suggesting that miR-148a also controls Bim expression in
repeatedly activated Th1 cells in vivo. According to the higher
expression of Bim, antagomir-148a led to a signiﬁcant depletion of
Th1 lymphocytes by 50% from the inﬂamed colon in vivo.Antagomir-148a-mediated depletion of Th cells was selective for
cells residing in the inﬂamed tissue, whereas Th lymphocytes from
the spleen were not affected.
Regarding disease pathology, antagomir-148a treatment resul-
ted in alleviation of inﬂammation as determined by a reduced
colonic weight-to-length ratio and delayed body weight loss in the
chronic late phase of colitis, while regeneration of colonic tissue in
terms of histopathology was not observed. Importantly, treatment
Fig. 5. Antagomir-148a treatment in the memory phase of acute immune responses does not alter the abundance and function of memory Th cells. (A) Schematic diagram
displaying antagomir treatment of mice in the memory phase following immunizations to elicit acute immune responses. (BeH) Mice were immunized with NP-CGG and IFA as
depicted in (A) or were left without immunization and antagomir treatment (non-immunized controls). On day 70, splenocytes were re-stimulated with NP-CGG before they were
stained for ﬂow cytometric analysis. Shown are representative dot plots with frequencies of NP-CGG-speciﬁc CD44þCD40Lþ memory T cells among CD3þCD4þ Th cells (B) and the
absolute cell numbers of CD40Lþ NP-CGG-speciﬁc Th memory cells in the spleen (C). (DeG) Shown are representative dot plots depicting the frequencies (D) and graphs with the
absolute cell numbers (EeG) of cytokine-expressing cells among NP-CGG-speciﬁc memory Th cells in the spleen. (H) Antibody titers of NP-CGG-speciﬁc IgG from blood sera of mice
treated as shown in (A) were determined by ELISA. Data in (BeG) are pooled from two independent experiments with n ¼ 10 (antagomir-148a), n ¼ 9 (antagomir-Scr) and n ¼ 6
(non-immunized) mice. Data in (H) are from one experiment with n ¼ 7 for antagomir-148a- and antagomir-Scr-treated mice each. Dot plots in (B) and (D) are representative for 2
independent experiments.
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Fig. 6. Antagomir-148a treatment does not alter the abundance of the accumulated, protective memory T cell pool in the bone marrow.Mice were treated as shown in Fig. 5A
or left without immunization and antagomir treatment as non-immunized controls. (A, B) Subsequently, mice were sacriﬁced to determine the accumulated, resting pools of CD4þ
(A) and CD8þ (B) T memory cells expressing CD69 and Ly6C in the bone marrow. (C, D) Representative dot plots of bone marrow cells following re-stimulation with NP-CGG to
determine the frequencies (C) and the absolute cell numbers (D) of NP-CGG-speciﬁc CD44þCD40Lþ Th memory cells. Dot plots in (C) are gated on CD4þ Th cells and representative
for 2 independent experiments. Data shown in (A) and (B) are pooled from 2 independent experiments with n ¼ 9 antagomir-Scr- and n ¼ 10 antagomir-148a-treated mice. Data in
(D) are from 2 independent experiments with n ¼ 6 non-immunized mice, as well as n ¼ 9 and n ¼ 10 antagomir-Scr- and antagomir-148a-treated mice, respectively.
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result in complete remission of mice either. Of note, in the model
used here, colitis progressed very rapidly, and remission was not
achieved, probably due to the composition of themicrobiota, which
contained segmented ﬁlamentous bacteria and helicobacter spe-
cies, both shown to promote colitis [33,34](data not shown). This is
in contrast to a previously published report of complete regener-
ation of mice after antibody-mediated ablation of Th cells 11 days
after treatment [35]. The function of the microbiota regarding dif-
ferences in disease quality and severity has been noted before, for
example, the microbiota dictates whether colitis is induced with
the transfer of T-bet-deﬁcient Th cells in Rag1/ mice [16,27]. In
our study, disease progression reached a terminal stage between 10
and 13 days after Th lymphocyte transfer. Thus, the time for
achieving complete remission as determined by tissue regeneration
was probably not enough [35]. Nonetheless, with this model we
could show that antagomir-148a treatment is capable of depleting
pro-inﬂammatory Th1 cells with a history of repeated activation
resulting in mild but signiﬁcant amelioration of inﬂammation in
the colon.
While the depletion of pro-inﬂammatory Th1 cells in ongoing
inﬂammationwas efﬁcient, wewondered whether antagomir-148atreatment is selective for these cells and spares protective memory.
Our data obtained from experiments with healthy, immunized
mice do not indicate that systemic antagomir-148a treatment in-
terferes with protective immune responses both during the effector
phase and the memory phase. This conclusion is based on equal
numbers and functionality (i.e. cytokine production) of NP-CGG-
speciﬁc T memory cells and the generation of speciﬁc IgG anti-
bodies. Importantly, not only the NP-CGG-speciﬁc T cell memory
but the global pool of resting T cell memory in BM and secondary
lymphoid organs, which had been generated by natural exposures
to antigens during life, was also not affected. Moreover, FoxP3þ
regulatory T cell numbers were also not altered by injection of
antagomir-148a, indicating that the balance between immunity
and tolerance was not skewed by this treatment. Taken together,
these experiments conﬁrm the selectivity of antagomir-148a for
repeatedly activated Th1 cells during chronic inﬂammation. These
data ﬁt to what we observed previously in vitro, namely, that
upregulated expression of miR-148a is conﬁned to repeatedly
activated Th1 cells to counterbalance the function of Bim which
otherwise drives these cells into apoptosis. Further, our results
corroborate the hypothesis that the mode of T cell activation (e.g.,
repeated or chronic activation of T cells) can be used as a
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while sparing resting memory T cells that are important in pro-
tecting the host from recurring infections [4,9].
The fact that we do not observe changes in the pool of memory T
cells and protective antibody titers upon treatment with
antagomir-148a is surprising to some degree, since miR-148a is
expressed by dendritic cells (DCs) [30] and by plasma cells [12]. It
has been shown that miR-148a represses the secretion of IL-12, IL-
6, TNF-a, IFN-b and the upregulation of MHC-class II in mature DCs
by targeting CaMKIIa (Calcium/calmodulin-dependent protein ki-
nase II). As a consequence, the expansion of T cells was reduced
[30]. We did not observe a signiﬁcant increase in numbers of
memory T cells after antagomir-148a treatment. The apparent
refraction of bone marrow-derived dendritic cells to antagomir-
148a treatment could be due to the fact that dendritic cells also
express miR-148b andmiR-152, which are inefﬁciently inhibited by
antagomir-148a [14] and might not depend on the miR-148/-152
family. Bim is also a target of miR-148a in plasma cells. However,
plasma cells in turn might be resistant to antagomir-148a treat-
ment because they depend more on the Mcl-1/Noxa than Bcl2/Bim
intrinsic apoptosis-pathway [36] for their survival and can poten-
tially survive antagomir-148a treatment.
Functions of miR-148a have also been reported in kidney
glomerular cells [29] and thrombocytes [37]. Histological analyses
of kidney sections did not reveal any pathological changes of their
architecture after antagomir-148a treatment, suggesting that the
viability of the kidney glomerular cells was not affected. MiR-148a
targets TULA-2 (T cell ubiquitin ligand-2) in thrombocytes and
antagonizing miR-148a expression in platelets decreases FcgRIIa
(Fc receptor for IgG IIA)-mediated activation and thrombosis in vivo
[37]. However, tissue sections of highly perfused organs, such as the
heart, kidney, lung and liver did not show any signs of tissue
damage or hemorrhage in these organs in C57BL/6 mice.
5. Conclusions
In summary, we show here that antagomir-148a has an
impressive therapeutic potential for the selective targeting of
repeatedly activated Th1 cells in chronic inﬂammatory diseases.
Applied systemically, antagomir-148a reaches intracellular con-
centrations sufﬁcient to knock-down miR-148a efﬁciently in such
Th1 cells, and depletes these cells from chronically inﬂamed tissue.
Taken together, antagomir-148a could be used as a tool for treating
chronic inﬂammatory diseases or other medical conditions that
depend on dysregulated miR-148a expression without putting pa-
tients at risk to fall short of opportunistic infections due to impaired
protective immunological memory.
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